Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it will demonstrate the Genedata Screener® Time-Series Extension (TSE) at the first annual SLAS Conference and Exhibition. Genedata Screener TSE is the industry’s first solution for integrated and interactive analysis of time-series data. It supports, in parallel, multiple read-outs from a range of experiments such as Calcium mobilization, Label-free, and Ion-channel assays. TSE’s single-platform integration with a variety of instruments streamlines workflows and improves the efficiency of data analysis in discovery research. Additional capabilities include enhanced support for Thermal Shift assays and improved visualization of time traces. Genedata Screener Tutorials will be presented and the Genedata Screener 10 with new extensions will be demonstrated at the SLAS Conference & Exhibition at the San Diego Convention Center (Booth #838; Feb. 4 – 8).
Genedata Screener TSE: Bridges the Gap between Instrument and Software
Time-series data are acquired through instruments that use specific detection technologies such as time-resolved fluorescence, surface plasmon resonance, planar waveguides, or trans-membrane current. Traditionally, data from these technologies are analyzed with the software associated with the read-out instrument. This approach fragments the research workflow and dilutes efficiency. Genedata Screener TSE is a single platform for screening data analysis and management that directly imports time-series data from instruments. It gives researchers full control over the complete analysis from trace aggregation (data reduction to yield per well results) to secondary analysis (e.g. hit list creation or dose-response curve fitting). Acting as a central hub for analyzing such experiments, Genedata Screener TSE helps to automate repetitive steps. The following are among TSE’s capabilities:
Genedata Screener TSE is a new module to the recently announced Genedata Screener version 10, which is used for Calcium mobilization (e.g. FLIPR), Label-free, and Ion-channel experiments. Designed for all plate-based screening data analysis, Genedata Screener 10 features additional extensions including: High Content Extension for high-content data integration, image access and display, feature combination, and clustering; and Cell Population Extension for interactive definition and aggregation of cell populations. These extensions are enabled by the new Genedata Screener 10 architecture, which advances the solution’s flexibility and easy adaptation to customer-specific experimental settings.
“Genedata Screener helps researchers push the envelope on productivity and efficiency in plate-based screening,” noted Dr. Othmar Pfannes, CEO of Genedata. “The ability to conduct data analysis on any type of time-dependent experiment from different technologies - all in one system - is unprecedented. Moreover, Genedata Screener 10 enables productivity gains and improves experiment results, which lifts the ROI for sophisticated screening technologies to new levels.”
[Note to Editors: No linkhandler TypoScript configuration found for key tt_news..: February 6, 2012 - “Genedata Screener, the First Choice for Integration and Analysis of High Content Data, Adds Tools for Cell-Level Data Analysis and Condensing”; February 7, 2012 – “Time-Dependent Data From Kinetics, Label-Free, and Ion-Channel Experiments Can All be Interactively Analyzed With Genedata Screener”]
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.